Get the Stockscreener App
124.51
1.21%
1.49
After Hours:
126.37
1.86
+1.49%
Spruce Biosciences Inc stock is traded at $124.51, with a volume of 200.71K.
It is up +1.21% in the last 24 hours and up +1,507% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
See More
Previous Close:
$123.02
Open:
$131.54
24h Volume:
200.71K
Relative Volume:
0.45
Market Cap:
$70.10M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-132.46
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
-3.88%
1M Performance:
+1,507%
6M Performance:
-86.69%
1Y Performance:
-90.34%
1-Day Range:
$118.10
$131.54
1-Week Range:
$112.95
$144.00
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
124.51 | 69.32M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.39 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.48 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.91 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.39 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.29 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
SPRB: JMP Securities Upgrades Spruce Biosciences to Market Outpe - GuruFocus
Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com Nigeria
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire
Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan
SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan
The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - healthcare-brew.com
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
Spruce Biosciences (SPRB): Analyst Raises Price Target Significa - GuruFocus
Spruce Biosciences stock price target raised to $160 from $10 at Leerink - Investing.com Philippines
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech
Mintz Advises the Placement Agents in Spruce Biosciences, Inc.’s $50 Million Private Placement - Mintz
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In - ts2.tech
Spruce Biosciences (NASDAQ:SPRB) Upgraded at Zacks Research - Defense World
SPRUCE BIOSCIENCES, INC. trading resumes - MSN
SPRB director steps down; company notes no disagreement - Stock Titan
Spruce Biosciences, Inc. Announces Resignation of Bali Muralidhar as Member of Board of Directors and as Member of the Compensation Committee of the Board, Effective October 15, 2025 - MarketScreener
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease - MSN
Head to Head Contrast: PyroGenesis Canada (NASDAQ:PYRGF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? - sharewise.com
Spruce Biosciences’ (SPRB) “Sell (D-)” Rating Reaffirmed at Weiss Ratings - Defense World
Spruce Biosciences insider filing shows 256-share buy, 1,050 held - Stock Titan
Spruce Biosciences to sell 502,181 shares at $68.00 in private placement - MSN
Spruce Biosciences (NASDAQ:SPRB) Shares Down 1% – What’s Next? - Defense World
Spruce Biosciences (NASDAQ:SPRB) Shares Down 1%What's Next? - MarketBeat
Medical Stocks To ConsiderOctober 6th - MarketBeat
Promising Pharmaceutical Stocks Worth WatchingOctober 6th - MarketBeat
$SPRB stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
Spruce Biosciences, Inc. announced that it has received $49.999769 million in funding - MarketScreener
Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 By Investing.com - Investing.com Canada
Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 - Investing.com India
SPRUCE BIOSCIENCES, INC. trading halted, volatility trading pause - MSN
Spruce Biosciences announces $50M private placement financing - TipRanks
Spruce Biosciences (SPRB) Secures $50M for Therapy Advancements - GuruFocus
Three Biotech Stocks Jump After Big Regulatory Wins - Finimize
Spruce Biosciences (SPRB) Secures $50M for Enzyme Replacement Th - GuruFocus
Spruce Biosciences to Raise $50 Million Through Private Placement; Shares Down Pre-Bell - MarketScreener
Spruce Biosciences (SPRB) Secures $50 Million for Enzyme Therapy Development - GuruFocus
Spruce Biosciences secures $50 million in private placement By Investing.com - Investing.com Canada
Spruce Biosciences secures $50 million in private placement - Investing.com
Spruce Biosciences (SPRB) Secures $50M in Private Placement for Therapy Advancement - GuruFocus
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy - MSN
Spruce Biosciences announces $50.0 million private placement financing - MarketScreener
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
Small Cap Stocks To Follow Today – October 6th - Defense World
Understanding the Current Trends in SPRB Stock - Info Petite Nation
Medical Stocks To Consider – October 6th - Defense World
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Spruce Biosciences Stock: Emergent Surges and Market Implications - timothysykes.com
SPRB Stock Hits 19-Month High Amid Trading Halts - NewsBreak: Local News & Alerts
Spruce Biosciences’ Breakthrough: Stock Skyrockets - StocksToTrade
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.28%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):